Mechanisms of cell growth regulation by heparin and heparan sulfate

Chemistry and Biology of Heparin and Heparan Sulfate

Volumn , Issue , 2005, Pages 533-570

  Nugent, Matthew A ^a   Forsten Williams, Kimberly ^b   Karnovsky, Morris J ^c   Edelman, Elazer R ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51849152679     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-008044859-6/50020-4     Document Type: Chapter

References (274)

1. Rabenstein DL Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002, 19:312-331.
2. Rosenberg RD, Damus PS The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973, 248:6490-6505.
3. Capila I, Linhardt RJ Heparin-protein interactions. Angew Chem Int Ed Engl 2002, 41:391-412.
4. Bjork I, Lindahl U Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982, 48:161-182.
5. Clowes AW, Karnovsky MJ Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
6. Conrad HE Heparin-Binding Proteins 1998, Academic Press, San Diego.
7. Gallagher JT Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 2001, 108:357-361.
8. Esko JD, Selleck SB Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002, 71:435-471.
9. Turnbull J, Powell A, Guimond S Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol 2001, 11:75-82.
10. Shriver Z, Liu D, Sasisekharan R Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc Med 2002, 12:71-77.
11. Iozzo RV, San Antonio JD Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001, 108:349-355.
12. Perrimon N, Bernfield M Specificities of heparan sulphate proteoglycans in developmental processes. Nature 2000, 404:725-728.
13. Robinson HC, Horner AA, Hook M, Ogren S, Lindahl U A proteoglycan form of heparin and its degradation to single-chain molecules. J Biol Chem 1978, 253:6687-6693.
14. Linhardt RJ, Ampofo SA, Fareed J, Hoppensteadt D, Mulliken JB, Folkman J Isolation and characterization of human heparin. Biochemistry 1992, 31:12441-12445.
15. Griffin CC, Linhardt RJ, Van Gorp CL, Toida T, Hileman RE, Schubert RL, Brown SE Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. Carbohydr Res 1995, 276:183-197.
16. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998, 20:156-167.
17. Gallagher JT, Turnbull JE, Lyon M Heparan sulphate proteoglycans: molecular organisation of membrane - associated species and an approach to polysaccharide sequence analysis. Adv Exp Med Biol 1992, 313:49-57.
18. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zaka M Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777.
19. Park PW, Reizes O, Bernfield M Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 2000, 275:29923-29926.
20. Subramanian SV, Fitzgerald ML, Bernfield M Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 1997, 272:14713-14720.
21. Rapraeger A, Bernfield M Cell surface proteoglycan of mammary epithelial cells. Protease releases a heparan sulfate-rich ectodomain from a putative membrane-anchored domain. J Biol Chem 1985, 260:4103-4109.
22. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 2000, 148:811-824.
23. Buczek-Thomas JA, Nugent MA Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures. A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bFGF binding following elastase-induced injury. J Biol Chem 1999, 274:25167-25172.
24. Iozzo RV Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652.
25. Richardson TP, Trinkaus-Randall V, Nugent MA Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci 2001, 114:1613-1623.
26. Hsia E, Richardson TP, Nugent MA Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling. J Cell Biochem 2003, 88:1214-1225.
27. Ishihara M, Fedarko NS, Conrad HE Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 1986, 261:13575-13580.
28. Fedarko NS, Conrad HE A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J Cell Biol 1986, 102:587-599.
29. Kovalszky I, Dudas J, Olah-Nagy J, Pogany G, Tovary J, Timar J, Kopper L, Jeney A, Iozzo RV Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 1998, 183:11-23.
30. Kolset SO, Prydz K, Pejler G Intracellular proteoglycans. Biochem J 2004, 379:217-227.
31. Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL Heparin is essential for the storage of specific granule proteases in mast cells. Nature 1999, 400:769-772.
32. Humphries DE, Wong GW, Friend DS, Gurish MF, Stevens RL 14 heparinnull transgenic mice are unable to store certain granule proteases in their mast cells. J Histochem Cytochem 1999, 47:1645D-1646D.
33. Segev A, Nili N, Strauss BH The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 2004, 63:603-610.
34. Nugent MA, Iozzo RV Fibroblast growth factor-2. Int J Biochem Cell Biol 2000, 32:115-120.
35. Fannon M, Forsten KE, Nugent MA Potentiation and inhibition of bFGF binding by heparin: A model for regulation of cellular response. Biochemistry 2000, 39:1434-1445.
36. Lemmon MA, Schlessinger J Transmembrane signaling by receptor oligomerization. Methods Mol Biol 1998, 84:49-71.
37. Fantl WJ, Johnson DE, Williams LT Signalling by receptor tyrosine kinases. Annu Rev Biochem 1993, 62:453-481.
38. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 1984, 223:1296-1299.
39. Burgess WH, Maciag T The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989, 58:575-606.
40. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM Cell surface, heparin-like molecules are required for binding basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.
41. Rapraeger A, Krufka A, Olwin B Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991, 252:1705-1708.
42. Nugent MA, Edelman ER Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperativity. Biochemistry 1992, 31:8876-8883.
43. Pantoliano MW, Horlick RA, Springer BA, Van Dyk DE, Tobery T, Wetmore DR, Lear JD, Nahapetian AT, Bradley JD, Sisk WP Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 1994, 33:10229-10248.
44. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M, Linhardt RJ Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 2004, 43:4724-4730.
45. Sperinde GV, Nugent MA Heparan sulfate proteoglycans control bFGF processing in vascular smooth muscle cells. Biochemistry 1998, 37:13153-13164.
46. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem 1992, 267:6093-6098.
47. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995, 270:11322-11326.
48. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
49. Gengrinovitch S, Berman B, David G, Witte L, Neufeld G, Ron D Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 1999, 274:10816-10822.
50. Goerges AL, Nugent MA Regulation of vascular endothelial growth factor binding and activity by extracellular pH. J Biol Chem 2003, 278:19518-19525.
51. Higashiyama S, Abraham JA, Klagsbrun M Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 1993, 122:933-940.
52. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC Activating and inhibitory heparin sequences for FGF-2 (basic FGF). J Biol Chem 1993, 268:23906-23914. Distinct requirements for FGF-1, FGF-2, and FGF-4.
53. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992, 267:10337-10341.
54. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 1998, 273:22936-22942.
55. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993, 259:1918-1921.
56. Loo BM, Kreuger J, Jalkanen M, Lindahl U, Salmivirta M Binding of heparin/heparan sulfate to fibroblast growth factor receptor 4. J Biol Chem 2001, 276:16868-16876.
57. Stauber DJ, DiGabriele AD, Hendrickson WA Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 2000, 97:49-54.
58. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000, 6:743-750.
59. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 2000, 101:413-424.
60. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M Structural basis for FGF receptor dimerization and activation. Cell 1999, 98:641-650.
61. Pellegrini L Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001, 11:629-634.
62. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407:1029-1034.
63. Lundin L, Larsson H, Kreuger J, Kanda S, Lindahl U, Salmivirta M, Claesson-Welsh L Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem 2000, 275:24653-24660.
64. Fannon M, Forsten-Williams K, Dowd CJ, Freedman DA, Folkman J, Nugent MA Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J 2003, 17:902-904.
65. Forsten KE, Fannon M, Nugent MA Potential mechanisms for the regulation of growth factor binding by heparin. J Theor Biol 2000, 205:215-230.
66. Forsten KE, Courant NA, Nugent MA Endothelial proteoglycans inhibit bFGF binding and mitogenesis. J Cell Physiol 1997, 172:209-220.
67. Gallagher JT Structure-activity relationship of heparan sulphate. Biochem Soc Trans 1997, 25:1206-1209.
68. Walker A, Turnbull JE, Gallagher JT Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 1994, 269:931-935.
69. Delehedde M, Lyon M, Gallagher JT, Rudland PS, Fernig DG Fibroblast growth factor-2 binds to small heparin-derived oligosaccharides and stimulates a sustained phosphorylation of p42/44 mitogen-activated protein kinase and proliferation of rat mammary fibroblasts. Biochem J 2002, 366:235-244.
70. Delehedde M, Seve M, Sergeant N, Wartelle I, Lyon M, Rudland PS, Fernig DG Fibroblast growth factor-2 stimulation of p42/44MAPK phosphorylation and IkappaB degradation is regulated by heparan sulfate/heparin in rat mammary fibroblasts. J Biol Chem 2000, 275:33905-33910.
71. Chua CC, Rahimi N, Forsten-Williams K, Nugent MA Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 2004, 94:316-323.
72. Padera R, Venkataraman G, Berry D, Godavarti R, Sasisekharan R FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: a compensation model for FGF-2 signaling. FASEB J 1999, 13:1677-1687.
73. Nugent MA, Karnovsky MJ, Edelman ER Vascular cell-derived heparan sulfate shows coupled inhibition of bFGF binding and mitogenesis in vascular smooth muscle cells. Circ Res 1993, 73:1051-1060.
74. Fannon M, Nugent MA FGF binds its receptors, is internalized and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem 1996, 271:17949-17956.
75. Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J Mammary Gland Biol Neoplasia 2001, 6:253-273.
76. Tkachenko E, Simons M Clustering induces redistribution of syndecan-4 core protein into raft membrane domains. J Biol Chem 2002, 277:19946-19951.
77. Tkachenko E, Lutgens E, Stan RV, Simons M Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci 2004, 117:3189-3199.
78. Chu CL, Buczek-Thomas JA, Nugent MA Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Biochem J 2004, 379:331-341.
79. Fuki IV, Meyer ME, Williams KJ Transmembrane and cytoplasmic domains of syndecan mediate a multistep endocytic pathway involving detergent-insoluble membrane rafts. Biochem J 2000, 351:607-612. (Part 3).
80. Fuki II, Iozzo RV, Williams KJ Perlecan heparan sulfate proteoglycan. A novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem 2000, 275:25742-25750.
81. Volk R, Schwartz JJ, Li J, Rosenberg RD, Simons M The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction. J Biol Chem 1999, 274:24417-24424.
82. Horowitz A, Murakami M, Gao Y, Simons M Phosphatidylinositol-4, 5-bisphosphate mediates the interaction of syndecan-4 with protein kinase C. Biochemistry 1999, 38:15871-15877.
83. Zhang Y, Li J, Partovian C, Sellke FW, Simons M Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol 2003, 284:H2078-H2082.
84. Oh ES, Woods A, Lim ST, Theibert AW, Couchman JR Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. J Biol Chem 1998, 273:10624-10629.
85. Horowitz A, Tkachenko E, Simons M Fibroblast growth factor-specific modulation of cellular response by syndecan-4. J Cell Biol 2002, 157:715-725.
86. Fedarko NS, Ishihara M, Conrad E Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan. J Cell Physiol 1989, 139:287-294.
87. Clevenger CV Nuclear localization and function of polypeptide ligands and their receptors: a new paradigm for hormone specificity within the mammary gland?. Breast Cancer Res 2003, 5:181-187.
88. Johnson HM, Subramaniam PS, Olsnes S, Jans DA Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. Bioessays 2004, 26:993-1004.
89. Watson K, Gooderham NJ, Davies DS, Edwards RJ Nucleosomes bind to cell surface proteoglycans. J Biol Chem 1999, 274:21707-21713.
90. Du Clos TW, Volzer MA, Hahn FF, Xiao R, Mold C, Searles RP Chromatin clearance in C57B1/10 mice: interaction with heparan sulphate proteoglycans and receptors on Kupffer cells. Clin Exp Immunol 1999, 117:403-411.
91. O'Farrell F, Loog M, Janson IM, Ek P Kinetic study of the inhibition of CK2 by heparin fragments of different length. Biochim Biophys Acta 1999, 1433:68-75.
92. Hathaway GM, Lubben TH, Traugh JA Inhibition of casein kinase II by heparin. J Biol Chem 1980, 255:8038-8041.
93. Bailly K, Soulet F, Leroy D, Amalric F, Bouche G Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J 2000, 14:333-344.
94. Amalric F, Bouche G, Bonnet H, Brethenou P, Roman AM, Truchet I, Quarto N Fibroblast growth Factor-2 (FGF-2) in the nucleus: Translocation process and targets. Biochem Pharm 1994, 47:111-115.
95. Jans DA, Hassan G Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling?. Bioessays 1998, 20:400-411.
96. Berry D, Lynn DM, Sasisekharan R, Langer R Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol 2004, 11:487-498.
97. Forsten KE, Akers RM, San Antonio JD Insulin-like growth factor (IGF) binding protein-3 regulation of IGF-I is altered in an acidic extracellular environment. J Cell Physiol 2001, 189:356-365.
98. Sperinde GV, Nugent MA Mechanisms of FGF-2 intracellular processing: a kinetic analysis of the role of heparan sulfate proteoglycans. Biochemistry 2000, 39:3788-3796.
99. Gleizes PE, Noaillac-Depeyre J, Dupont MA, Gas N Basic fibroblast growth factor (FGF-2) is addressed to caveolae after binding to the plasma membrane of BHK cells. Eur J Cell Biol 1996, 71:144-153.
100. Gleizes PE, Noaillac-Depeyre J, Amalric F, Gas N Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglycans-mediated pathway: an ultrastructural approach. Eur J Cell Biol 1995, 66:47-59.
101. Reilly JF, Mizukoshi E, Maher PA Ligand dependent and independent internalization and nuclear translocation of fibroblast growth factor (FGF) receptor 1. DNA Cell Biol 2004, 23:538-548.
102. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am J Pathol 1988, 130:393-400.
103. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai-Michaeli R, Sasse J, Klagsbrun M Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into the subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987, 84:2292-2296.
104. Whalen GF, Shing Y, Folkman J The fate of intravenously administered bFGF and the effect of heparin. Growth Factors 1989, 1:157-164.
105. Friedl A, Filla M, Rapraeger AC Tissue-specific binding by FGF and FGF receptors to endogenous heparan sulfates. Methods Mol Biol 2001, 171:535-546.
106. Friedl A, Chang Z, Tierney A, Rapraeger AC Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol 1997, 150:1443-1455.
107. Gospodarowicz D, Cheng J Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986, 128:475-484.
108. Edelman ER, Nugent MA Controlled release of basic fibroblast growth factor. Drug News and Perspectives 1991, 4:352-357.
109. Sommer A, Rifkin DB Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989, 138:215-220.
110. Saksela O, Moscatelli D, Sommer A, Rifkin DB Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988, 107:743-751.
111. Gitay-Goren H, Cohen T, Tessler S, Soker S, Gengrinovitch S, Rockwell P, Klagsbrun M, Levi BZ, Neufeld G Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem 1996, 271:5519-5523.
112. Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz AZF, Vlodavsky I Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol 1989, 109:823-831.
113. Nugent MA, Edelman ER Transforming growth factor β1 stimulates the production of basic fibroblast growth factor binding proteoglycans in Balb/c3T3 cells. J Biol Chem 1992, 267:21256-21264.
114. Presta M, Maier JAM, Rusnati M, Ragnotti G Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989, 140:68-74.
115. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman JIV Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989, 28:1737-1743.
116. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer and Metast Rev 1990, 9:203-226.
117. Rich CB, Nugent MA, Stone P, Foster JA Elastase release of basic fibroblast growth factor in pulmonary fibroblast cultures results in down regulation of elastin gene transcription. J Biol Chem 1996, 271:23043-23048.
118. Liu J, Rich CB, Buczek-Thomas JA, Nugent MA, Panchenko MP, Foster JA Heparin-binding EGF-like growth factor regulates elastin and FGF-2 expression in pulmonary fibroblasts. Am J Physiol Lung Cell Mol Physiol 2003, 285:L1106-L1115.
119. Buczek-Thomas JA, Lucey EC, Stone PJ, Chu CL, Rich CB, Carreras I, Goldstein RH, Foster JA, Nugent MA Elastase mediates the release of growth factors from lung in vivo. Am J Respir Cell Mol Biol 2004, 31:344-350.
120. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998, 65:1540-1544.
121. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999, 100:1865-1871.
122. Edelman ER, Mathiowitz E, Langer R, Klagsbrun M Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991, 12:619-626.
123. Nugent MA, Chen OS, Edelman ER Controlled release of fibroblast growth factor: activity in cell culture. Mat Res Soc Symp Proc 1992, 252:273-284.
124. Moscatelli D Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfate but slowly from receptors. J Biol Chem 1992, 267:25803-25809.
125. Dowd CJ, Cooney CL, Nugent MA Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem 1999, 274:5236-5244.
126. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 2004, 101:4833-4838.
127. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP QSulf1 remodels the 6-O-sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 2003, 162:341-351.
128. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001, 293:1663-1666.
129. Izvolsky KI, Zhong L, Wei L, Yu Q, Nugent MA, Cardoso WV Heparan sulfates expressed in the distal lung are required for Fgf10 binding to the epithelium and for airway branching. Am J Physiol Lung Cell Mol Physiol 2003, 285:L838-L846.
130. Izvolsky KI, Shoykhet D, Yang Y, Yu Q, Nugent MA, Cardoso WV Heparan sulfate-FGF10 interactions during lung morphogenesis. Dev Biol 2003, 258:185-200.
131. Goerges AL, Nugent MA pH regulates vascular endothelial growth factor binding to fibronectin: a mechanism for control of extracellular matrix storage and release. J Biol Chem 2004, 279:2307-2315.
132. Lin X, Buff EM, Perrimon N, Michelson AM Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development 1999, 126:3715-3723.
133. Lin X, Perrimon N Developmental roles of heparan sulfate proteoglycans in Drosophila. Glycoconj J 2002, 19:363-368.
134. San Antonio JD, Slover J, Lawler J, Karnovsky MJ, Lander AD Specificity in the interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin. Biochemistry 1993, 32:4746-4755.
135. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor binding, mitogenesis, and angiogenesis. Cell 1994, 79:1005-1013.
136. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998, 102:1599-1608.
137. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 1999, 18:163-178.
138. Nugent MA, Nugent HM, Iozzo RV, Sanchack K, Edelman ER Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 2000, 97:6722-6727.
139. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996, 271:10079-10086.
140. Weiser MC, Belknap JK, Grieshaber SS, Kinsella MG, Majack RA Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol 1996, 15:331-340.
141. Belknap JK, Weiser-Evans MC, Grieshaber SS, Majack RA, Stenmark KR Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature. Am J Respir Cell Mol Biol 1999, 20:24-34.
142. Kinsella MG, Tran PK, Weiser-Evans MC, Reidy M, Majack RA, Wight TN Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 2003, 23:608-614.
143. Castellot JJ, Addonizio ML, Rosenberg RD, Karnovsky MJ Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle growth. J Cell Biol 1981, 90:372-379.
144. Castellot JJ, Beeler DL, Rosenberg RD, Karnovsky MJ Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984, 120:315-320.
145. Castellot JJ, Wong K, Herman B, Hoover RL, Albertini DF, Wright TC, Caleb BL, Karnovsky MJ Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985, 124:13-20.
146. Castellot JJ, Rosenberg RD, Karnovsky MJ Endothelium, heparin, and the regulation of vascular smooth muscle cell growth. Biology of Endothelial Cells 1984, 118-128. Martinus Nijhoff Publishers, Boston. E.A. Jaffe (Ed.).
147. Clowes AW, Karnovsky MJ Suppression by heparin of injury-induced myointimal thickening. J Surg Res 1978, 24:161-168.
148. Castellot JJ, Wright TC, Karnovsky MJ Regulation of vascular smooth muscle cell growth by heparin and heparan sulfate. Semin Thromb Hemost 1987, 13:489-503.
149. Tran PK, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, Hedin U Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 2004, 94:550-558.
150. Bingley JA, Hayward IP, Campbell JH, Campbell GR Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 1998, 28:308-318.
151. Bingley JA, Campbell JH, Hayward IP, Campbell GR Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann NY Acad Sci 1997, 811:238-244.
152. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Hook M, Reed CC, Iozzo RV Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004, 166:97-109.
153. Gonzalez EM, Mongiat M, Slater SJ, Baffa R, Iozzo RV A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J Biol Chem 2003, 278:38113-38116.
154. Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 2003, 278:17491-17499.
155. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003, 278:4238-4249.
156. Ghiselli G, Eichstetter I, Iozzo RV A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem J 2001, 359:153-163.
157. Moehren G, Markevich N, Demin O, Kiyatkin A, Goryanin I, Hoek JB, Kholodenko BN Temperature dependence of the epidermal growth factor receptor signaling network can be accounted for by a kinetic model. Biochemistry 2002, 41:306-320.
158. Wiley HS, Shvartsman SY, Lauffenburger DA Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 2003, 13:43-50.
159. Kholodenko BN, Demin OV, Moehren G, Hoek JB Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999, 274:30169-30181.
160. Park CS, Schneider IC, Haugh JM Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts. J Biol Chem 2003, 278:37064-37072.
161. Forsten-Williams K, Chua CC, Nugent MA The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. J Theo Biol 2005, 483-499.
162. Filion RJ, Popel AS A reaction-diffusion model of basic fibroblast growth factor interactions with cell surface receptors. Ann Biomed Eng 2004, 32:645-663.
163. Mac Gabhann F, Popel AS Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of Neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol 2005, 288:H2851-H2860.
164. Mac Gabhann F, Popel AS Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286:H153-H164.
165. Patton WA, Granzow CA, Getts LA, Thomas SC, Zotter LM, Gunzel KA, Lowe-Krentz LJ Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem J 1995, 311:461-469. (Part 2).
166. Glimelius B, Busch C, Hook M Binding of heparin on the surface of cultured human endothelial cells. Thromb Res 1978, 12:773-782.
167. Castellot JJ, Cochran DL, Karnovsky MJ Effect of heparin on vascular smooth muscle cells. I. Cell metabolism. J Cell Physiol 1985, 124:21-28.
168. Letourneur D, Caleb BL, Castellot JJ Heparin binding, internalization, and metabolism in vascular smooth muscle cells. I. Upregulation of heparin binding correlates with antiproliferative activity. J Cell Physiol 1995, 165:676-686.
169. Letourneur D, Caleb BL, Castellot JJ Heparin binding, internalization, and metabolism in vascular smooth muscle cells. II. Degradation and secretion in sensitive and resistant cells. J Cell Physiol 1995, 165:687-695.
170. Karnovsky MJ, Wright TC, Castellot JJ, Choay J, Lormeau JC, Petitou M Heparin, heparan sulfate, smooth muscle cells, and atherosclerosis. Ann NY Acad Sci 1989, 556:268-281.
171. Delmolino LM, Castellot JJ Heparin suppresses sgk, an early response gene in proliferating vascular smooth muscle cells. J Cell Physiol 1997, 173:371-379.
172. Mishra-Gorur K, Castellot JJ Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells. J Cell Physiol 1999, 178:205-215.
173. Mishra-Gorur K, Singer HA, Castellot JJ Heparin inhibits phosphorylation and autonomous activity of Ca(2+)/calmodulin-dependent protein kinase II in vascular smooth muscle cells. Am J Pathol 2002, 161:1893-1901.
174. Daum G, Hedin U, Wang Y, Wang T, Clowes AW Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells. Circ Res 1997, 81:17-23.
175. Pukac LA, Castellot JJ, Wright TC, Caleb BL, Karnovsky MJ Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. Cell Regul 1990, 1:435-443.
176. Horowitz A, Simons M Regulation of syndecan-4 phosphorylation in vivo. J Biol Chem 1998, 273:10914-10918.
177. Horowitz A, Simons M Phosphorylation of the cytoplasmic tail of syndecan-4 regulates activation of protein kinase Calpha. J Biol Chem 1998, 273:25548-25551.
178. Oh ES, Couchman JR, Woods A Serine phosphorylation of syndecan-2 proteoglycan cytoplasmic domain. Arch Biochem Biophys 1997, 344:67-74.
179. Oh ES, Woods A, Couchman JR Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem 1997, 272:11805-11811.
180. Oh ES, Woods A, Couchman JR Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 1997, 272:8133-8136.
181. Lee D, Oh ES, Woods A, Couchman JR, Lee W Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5-bisphosphate. J Biol Chem 1998, 273:13022-13029.
182. Kinnunen T, Kaksonen M, Saarinen J, Kalkkinen N, Peng HB, Rauvala H Cortactin-Src kinase signaling pathway is involved in N-syndecan-dependent neurite outgrowth. J Biol Chem 1998, 273:10702-10708.
183. Lebakken CS, McQuade KJ, Rapraeger AC Syndecan-1 signals independently of betal integrins during Raji cell spreading. Exp Cell Res 2000, 259:315-325.
184. Beauvais DM, Rapraeger AC Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004, 2:3.
185. Beauvais DM, Burbach BJ, Rapraeger AC The syndecan-1 ectodomain regulates α v β3 integrin activity in human mammary carcinoma cells. J Cell Biol 2004, 167:171-181.
186. Asthagiri AR, Nelson CM, Horwitz AF, Lauffenburger DA Quantitative relationship among integrin-ligand binding, adhesion, and signaling via focal adhesion kinase and extracellular signal-regulated kinase 2. J Biol Chem 1999, 274:27119-27127.
187. O'Keefe JH, Hartzler GO Restenosis after coronary angioplasty. J Inv Car 1989, 1:109-122.
188. McBride W, Lange RA, Hillis LD Restenosis after successful coronary angioplasty: pathophysiology and prevention. New Engl J Med 1988, 318:1734-1738.
189. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle proliferation. J Am Coll Cardiol 1990, 15:1667-1687.
190. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R New approaches to preventing restenosis. BMJ 2003, 327:274-279.
191. Losordo DW, Isner JM, Diaz-Sandoval LJ Endothelial recovery: the next target in restenosis prevention. Circulation 2003, 107:2635-2637.
192. http://www.americanheartorg2000:Heart_and_Stroke_A_Z_Guide/cvds.html.
193. Association AH Heart Disease and Stroke Statistics - 2004 Update 2004, 1-52. American Heart Association, Inc, Dallas.
194. Ross R, Glomset JA The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976, 295:369-377.
195. Ross R The pathogenesis of atherosclerosis - an update. N Engl J Med 1986, 314:488-500.
196. Ross R The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-808.
197. Ross R Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126. [see comments].
198. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 1999, 84:462-466.
199. Fishman JA, Ryan GB, Karnovsky MJ Endothelial regeneration in the rat carotid artery and significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975, 32:339-351.
200. Clowes AW, Reidy MA, Clowes MM Kinetics of cellular proliferation after arterial injury I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983, 49:327-333.
201. Clowes AW, Clowes MM Kinetics of cellular proliferation after arterial injury II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985, 52:611-616.
202. Hales CA, Kradin RL, Brandstetter RD, Zhu YJ Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 1983, 128:747-751.
203. Hirsch GM, Karnovsky MJ Inhibition of vein graft intimal proliferative lesions in the rat by heparin. Am J Pathol 1991, 139:581-587.
204. Hopwood J, Hook M, Linker A, Lindahl U Anticoagulant activity of heparin: isolation of antithrombin-binding sites. FEBS Lett 1976, 69:51-54.
205. Beeler D, Rosenberg R, Jordan R Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979, 254:2902-2913.
206. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ Inhibition of rat arterial smooth muscle cell proliferation by heparin I. In vivo studies with anticoagulant and non-anticoagulant heparin. Circ Res 1980, 46:625-634.
207. Hoover RL, Rosenberg R, Haering W, Karnovsky MJ Inhibition of rat arterial smooth muscle cell proliferation by heparin II. In vitro studies. Circ Res 1980, 47:578-583.
208. Benitz WE, Lessler DS, Coulson JD, Bernfield M Heparin inhibits proliferation of fetal vascular smooth muscle cells in the absence of platelet-derived growth factor. J Cell Physiol 1986, 127:1-7.
209. Castellot JJ, Hoover RL, Harper PA, Karnovsky MJ Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation. Am J Pathol 1985, 120:427-435.
210. Clowes AW, Clowes MM Kinetics of cellular proliferation after arterial injury II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985, 52:611-616.
211. Majesky MW, Schwartz SM, Clowes MM, Clowes AW Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987, 61:296-300.
212. Kinsella MG, Irvin C, Reidy MA, Wight TN Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 2004, 175:51-57.
213. Francis DJ, Parish CR, McGarry M, Santiago FS, Lowe HC, Brown KJ, Bingley JA, Hayward IP, Cowden WB, Campbell JH, Campbell GR, Chesterman CN, Khachigian LM Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ Res 2003, 92:e70-e77.
214. Myler HA, West JL Heparanase and platelet factor-4 induce smooth muscle cell proliferation and migration via bFGF release from the ECM. J Biochem (Tokyo) 2002, 131:913-922.
215. Silver PJ, Moreau JP, Denholm E, Lin YQ, Nguyen L, Bennett C, Recktenwald A, DeBlois D, Baker S, Ranger S Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo. Eur J Pharmacol 1998, 351:79-83.
216. Campbell JH, Rennick RE, Kalevitch SG, Campbell GR Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype. Exp Cell Res 1992, 200:156-167.
217. Edelman ER, Adams DA, Karnovsky MJ Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA 1990, 87:3773-3777.
218. Edelman ER, Karnovsky MJ Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 1994, 89:770-776.
219. Rogers C, Karnovsky MJ, Edelman ER Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation 1993, 88:1215-1221.
220. Wright TC, Castellot JJ, Petitou M, Lormeau J-C, Choay J, Karnovsky MJ Structural determinants of heparin's growth inhibitory activity. J Biol Chem 1989, 264:1534-1542.
221. Edelman ER, Karnovsky MJ Heparin/heparan sulfate regulation of vascular smooth muscle cell behavior. Airway and Vascular Remodeling in Asthma and Cadiovascular Diseases: Implications for Therapeutic Interventions 1994, 45-70. Academic Press, London. C. Page, J. Black (Eds.).
222. Fritze L, Reilly C, Rosenberg R An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol 1985, 100:1041-1049.
223. Bjornsson TD, Dryjski M, Tluczek J, Mennie R, Ronan J, Mellin TN, Thomas KA Acidic fibroblast growth factor promotes vascular repair. PNAS (USA) 1991, 88:8661-8665.
224. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM Local delivery of vascular endothelial growth factor accelerates re-endothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995, 91:2793-2801.
225. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996, 94:3291-3302.
226. Swanson N, Hogrefe K, Javed Q, Malik N, Gershlick AH Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia. J Invasive Cardiol 2003, 15:688-692.
227. Van Belle E, Tio FO, Chen D, Maillard L, Kearney M, Isner JM Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997, 29:1371-1379.
228. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Yla-Herttuala S Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683.
229. Edelman ER, Pukac LA, Karnovsky MJ Protamine and protamine insulins exacerbate vascular injury. J Clin Invest 1993, 91:2308-2313.
230. Lindner V, Olson NE, Clowes AW, Reidy MA Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 1992, 90:2044-2049.
231. Lindner V, Reidy MA Role of basic fibroblast growth factor in proliferation of endothelium and smooth muscle after denuding injury in vivo. Exs 1992, 61:386-388.
232. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest 1992, 89:465-473.
233. Schmidt A, Yoshida K, Buddecke E The antiproliferative activity of arterial heparan sulfate residues in domains enriched with 2-O-sulfated uronic acid residues. J Biol Chem 1992, 267:19242-19247.
234. Schmidt A, Lemming G, Yoshida K, Buddecke E Molecular organization and antiproliferative domains of arterial tissue heparan sulfate. Eur J Cell Biol 1992, 59:322-328.
235. Nader HB, Buonassisi V, Colburn P, Dietrich CP Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. J Cell Physiol 1989, 140:305-310.
236. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992, 12:112-127.
237. Ishai-Michaeli R, Eldor A, Vlodavsky I Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul 1990, 1:833-842.
238. Mulloy B, Linhardt RJ Order out of complexity - protein structures that interact with heparin. Curr Opin Struct Biol 2001, 11:623-628.
239. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991, 68:106-113.
240. Edelman ER, Nugent MA, Karnovsky MJ Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA 1993, 90:1513-1517.
241. Schwartz SM, Gajdusek CM, Reidy MA, Selden SCd, Haudenschild CC Maintenance of integrity in aortic endothelium. Fed Proc 1980, 39:2618-2625.
242. Rubanyi GM The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993, 22:S1-S14.
243. Schwartz SM, Reidy MA, O'Brien ER Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995, 74:541-551.
244. Han RO, Ettenson DS, Koo EW, Edelman ER Heparin/heparan sulfate chelation inhibits control of vascular repair by tissue-engineered endothelial cells. Am J Physiol 1997, 273:H2586-H2595.
245. Nugent HM, Rogers C, Edelman ER Endothelial implants inhibit intimal hyperplasia after porcine angioplasty. Circ Res 1999, 84:384-391.
246. Zacharski LR, Ornstein DL, Mamourian AC Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000, 26(Suppl 1):69-77.
247. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999, 82:947-952.
248. Cosgrove RH, Zacharski LR, Racine E, Andersen JC Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002, 28:79-87.
249. Bobek V, Kovarik J Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004, 58:213-219.
250. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS Robbins and Cotran Pathologic Basis of Disease 2005, Elsevier Saunders, Philadelphia. 7th ed.
251. Liu D, Shriver Z, Qi Y, Venkataraman G, Sasisekharan R Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 2002, 28:67-78.
252. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2:521-528.
253. Smorenburg SM, Van Noorden CJ The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001, 53:93-105.
254. Castelli R, Porro F, Tarsia P The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004, 9:205-213.
255. Sanderson RD Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001, 12:89-98.
256. Filmus J Glypicans in growth control and cancer. Glycobiology 2001, 11:19R-23R.
257. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 2002, 99:568-573.
258. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998, 273:51-57.
259. Iozzo RV Presence of unsulfated heparan chains on the heparan sulfate proteoglycan of human colon carcinoma cells. Implications for heparan sulfate proteoglycan biosynthesis. J Biol Chem 1989, 264:2690-2699.
260. DeBaun MR, Ess J, Saunders S Simpson Golabi Behmel syndrome: progress toward understanding the molecular basis for overgrowth, malformation, and cancer predisposition. Mol Genet Metab 2001, 72:279-286.
261. Folkman J Angiogenesis-dependent diseases. Semin Oncol 2001, 28:536-542.
262. Dvorak HF Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
263. Levene CI, Kapoor R, Heale G The effect of hypoxia on the synthesis of collagen and glycosaminoglycans by cultured pig aortic endothelium. Atherosclerosis 1982, 44:327-337.
264. Li J, Shworak NW, Simons M Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. J Cell Sci 2002, 115:1951-1959.
265. Furuta GT, Dzus AL, Taylor CT, Colgan SP Parallel induction of epithelial surface-associated chemokine and proteoglycan by cellular hypoxia: implications for neutrophil activation. J Leukoc Biol 2000, 68:251-259.
266. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997, 108:263-268.
267. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001, 61:6020-6024.
268. Jain RK Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
269. Venkataraman G, Shriver Z, Raman R, Sasisekharan R Sequencing complex polysaccharides. Science 1999, 286:537-542.
270. Nugent MA Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci USA 2000, 97:10301-10303.
271. Sears P, Wong CH Toward automated synthesis of oligosaccharides and glycoproteins. Science 2001, 291:2344-2350.
272. Plante OJ, Palmacci ER, Seeberger PH Automated solid-phase synthesis of oligosaccharides. Science 2001, 291:1523-1527.
273. Naggar EF, Costello CE, Zaia J Competing fragmentation processes in tandem mass spectra of heparin-like glycosaminoglycans. J Am Soc Mass Spectrom 2004, 15:1534-1544.
274. Zaia J, Li XQ, Chan SY, Costello CE Tandem mass spectrometric strategies for determination of sulfation positions and uronic acid epimerization in chondroitin sulfate oligosaccharides. J Am Soc Mass Spectrom 2003, 14:1270-1281.